6 min read

WHEN MEDICINE BECOMES POISON: WHO IS PROTECTING NIGERIANS FROM FAKE DRUGS?

THREE BOTTLES, ONE LABEL, DIFFERENT CONTENTS — A DISTURBING DISCOVERY RAISES URGENT QUESTIONS ABOUT DRUG SAFETY, PHARMACEUTICAL REGULATION AND THE LIVES OF MILLIONS OF NIGERIANS

By Dr. (The Rt. Hon.) Okey Umeano Medical Doctor | Former Member, House of Representatives, Third Republic

8 October 2026 | Opinion & Call for Investigation

0:00
/2:38

There is something profoundly frightening about a country in which a sick person must first investigate the authenticity of a medicine before swallowing it.

A patient visits a hospital, receives a diagnosis, obtains a prescription, walks into a pharmacy, pays for the prescribed medication and returns home believing that treatment has begun.

But what if the medicine is not what its label claims?

What if the tablets contain insufficient active ingredients?

What if the syrup has deteriorated?

What if the product is counterfeit?

And what if the patient dies, not because the doctor made a wrong diagnosis, but because the medicine administered was incapable of treating the disease?

THIS IS THE QUESTION NIGERIA MUST CONFRONT.

Recently, an alarming observation was brought to attention.

Three bottles of supposedly the same pharmaceutical product carried the same product label. Yet their appearances, colours, textures and contents were noticeably different.

Three bottles.

One product identity.

Different physical characteristics.

How can this happen?

There may be legitimate explanations, including manufacturing changes or differences between production batches. There may also be serious explanations involving deterioration, substandard manufacturing, improper storage or counterfeiting.

Without laboratory analysis, no responsible person can declare those particular bottles fake.

But the observation is sufficiently troubling to justify an investigation.

And it raises a much larger national question.

HOW MANY NIGERIANS ARE SWALLOWING MEDICINES WHOSE QUALITY THEY CANNOT VERIFY?

THE SILENT DANGER INSIDE THE MEDICINE BOTTLE

Nigeria's struggle against falsified and substandard medicines is not merely a commercial problem.

It is a matter of life and death.

Consider the hypertensive patient who faithfully takes prescribed medication but whose blood pressure remains dangerously uncontrolled because the product contains less active ingredient than required.

Consider the diabetic whose blood sugar rises despite apparent compliance with treatment.

Consider the child with pneumonia who receives an antibiotic that does not contain the necessary therapeutic concentration.

Consider the pregnant woman being treated for a serious infection.

Consider the elderly patient whose family spends its limited income purchasing medicines that may be ineffective.

In each case, treatment failure can be wrongly attributed to the patient's disease, the doctor's judgment or the supposed resistance of the illness.

Meanwhile, the quality of the medicine itself may never be investigated.

That possibility should disturb every Nigerian.

WHERE IS NAFDAC? WHERE IS THE ACCOUNTABILITY?

The National Agency for Food and Drug Administration and Control, NAFDAC, has the statutory responsibility to regulate medicines and combat falsified and substandard pharmaceutical products.

Its work is essential, and its enforcement efforts deserve institutional support.

But Nigerians are entitled to ask difficult questions.

How effectively are pharmaceutical products monitored after entering the market?

How frequently are samples purchased anonymously from pharmacies and subjected to independent laboratory testing?

What happens when a suspicious batch is discovered?

How quickly are healthcare professionals and the public informed?

Can an ordinary Nigerian readily determine whether a medicine has been recalled?

And when a falsified product is discovered, how far does the investigation travel through the distribution chain?

Does enforcement stop with the retailer, or does it reach the importer, manufacturer, wholesaler and criminal network responsible?

A DRUG REGULATORY SYSTEM MUST BE JUDGED NOT ONLY BY THE PRODUCTS IT APPROVES, BUT ALSO BY ITS ABILITY TO DETECT DANGEROUS PRODUCTS AFTER APPROVAL.

A NAFDAC registration number printed on a package is not, by itself, proof that the particular package is genuine. Counterfeiters can reproduce labels and registration details.

The country therefore needs effective product authentication, surveillance, traceability and transparent enforcement.

WHEN A DOCTOR PRESCRIBES CORRECTLY BUT THE MEDICINE FAILS

As a medical practitioner, I find one aspect of this problem particularly disturbing.

Medical treatment depends on several interconnected responsibilities.

The doctor must diagnose correctly.

The pharmacist must dispense correctly.

The manufacturer must produce medicines of acceptable quality.

The distributor must preserve the integrity of the product.

The regulator must enforce standards.

And the patient must follow the treatment instructions.

When one of these responsibilities fails, the entire treatment process is endangered.

A doctor may prescribe the correct antibiotic, in the correct dose, for the correct duration.

But if the medicine contains an inadequate quantity of active ingredient, treatment may fail despite appropriate clinical management.

Substandard antimicrobial medicines can also contribute to antimicrobial resistance.

The implications extend beyond individual patients.

They threaten the credibility of medical practice, the effectiveness of national disease-control programmes and public confidence in healthcare.

THE ECONOMICS OF FAKE MEDICINES: PROFITS FOR CRIMINALS, SUFFERING FOR FAMILIES

Counterfeit medicines are particularly cruel because they exploit human vulnerability.

A person purchasing medicine is often already sick, frightened or desperate.

Families borrow money to pay hospital bills.

Parents sacrifice necessities to purchase treatment for their children.

Pensioners spend limited savings on essential medicines.

When falsified medicines enter the supply chain, the economic damage goes beyond the purchase price.

Patients may require additional consultations, hospital admission, laboratory investigations or emergency treatment.

Some may suffer permanent complications.

Others may lose their lives.

And behind every preventable death is a family that must bear the consequences.

THE PROFIT FROM A FALSIFIED MEDICINE MAY GO TO ONE CRIMINAL NETWORK. THE COST OF ITS FAILURE MAY BE PAID BY AN ENTIRE FAMILY.

WHAT THE FEDERAL GOVERNMENT MUST DO NOW

Nigeria requires a stronger, transparent and measurable national pharmaceutical-quality assurance system.

I call for the following urgent actions:

1. Independent investigation: NAFDAC should examine credible reports of products with inconsistent physical characteristics and conduct laboratory testing where indicated.

2. Routine market surveillance: Medicines should be sampled from pharmacies, hospitals, wholesalers and informal markets using risk-based and random testing.

3. Public batch-level recall information: Nigerians should have easy access to current notices identifying affected medicines, manufacturers and batch numbers.

4. Supply-chain traceability: Regulators should strengthen systems capable of tracing pharmaceutical products from manufacturers and importers to distributors and retailers.

5. Stronger prosecution: Those found responsible for deliberately manufacturing or distributing falsified medicines should face effective enforcement and appropriate criminal sanctions.

6. Protection for whistleblowers: Pharmacists, doctors, patients and distributors who report suspicious products should be able to do so safely.

7. Public education: Nigerians should be taught how to identify warning signs, use official verification systems and report suspected substandard medicines.

These actions require cooperation among NAFDAC, the Pharmacists Council of Nigeria, professional medical associations, law-enforcement agencies, manufacturers and consumer organisations.

THREE BOTTLES SHOULD NOT BE IGNORED

Let us return to the three bottles that prompted this concern.

The first responsibility is to preserve the evidence.

The bottles, labels, batch numbers, expiry dates, purchase receipts and remaining contents should be retained.

Their manufacturing and distribution histories should be established.

Samples should be examined by an accredited laboratory.

If the bottles belong to different production batches, legitimate formulation or manufacturing changes must be considered.

If they belong to the same batch yet exhibit significant unexplained differences, that would warrant particular scrutiny.

The purpose must be to establish facts, not merely to create alarm.

Because a responsible investigation does not begin by declaring guilt.

It begins by demanding evidence.

THE RIGHT TO SAFE MEDICINE IS THE RIGHT TO LIFE

Nigeria cannot build a credible healthcare system if the quality of essential medicines remains uncertain.

We cannot expect doctors to deliver successful treatment when the pharmaceutical supply chain is compromised.

We cannot expect patients to trust hospitals when treatment failure may arise from defective medicines.

And we cannot expect families to continue paying enormous medical bills without assurance that the products they purchase meet established standards.

This is a matter that deserves attention from the Presidency, the National Assembly, the Federal Ministry of Health and Social Welfare, NAFDAC and every state government.

The National Assembly should demand clear, publicly available information on pharmaceutical surveillance, confirmed falsification incidents, recalls, prosecutions and regulatory outcomes.

It should also ensure that regulatory institutions have the resources and independence necessary to perform their duties.

Nigeria must make it increasingly difficult for dangerous medicines to reach patients and increasingly easy for citizens to verify what they purchase.

MY FINAL QUESTION TO NIGERIA

What is the value of building hospitals if the medicines supplied to those hospitals cannot always be trusted?

What is the value of training doctors and pharmacists if criminal falsification can undermine their work?

What is the value of healthcare regulation if citizens remain exposed to dangerous pharmaceutical products?

And what is the value of government if the sick cannot be adequately protected from those who profit by exploiting their suffering?

WE MUST NEVER ACCEPT A NIGERIA WHERE A PATIENT GOES TO THE PHARMACY SEEKING LIFE AND RETURNS HOME CARRYING AN UNRECOGNISED DANGER.

The three suspicious bottles may ultimately have an innocent explanation. Or they may expose a serious breach in pharmaceutical quality.

Either way, they deserve proper examination.

The lives of Nigerians are too precious for assumptions, complacency or regulatory silence.

LET NAFDAC INVESTIGATE.

LET THE EVIDENCE SPEAK.

LET THE PHARMACEUTICAL SUPPLY CHAIN BE ACCOUNTABLE.

AND ABOVE ALL, LET THE MEDICINE MEANT TO SAVE A NIGERIAN LIFE NEVER BECOME THE INSTRUMENT THAT DESTROYS IT.

Dr. (The Rt. Hon.) Okey Umeano Medical Doctor Former Member, House of Representatives, Third Republic Public Affairs Commentator

Editorial note: This article is a public-health commentary and call for investigation. The three-bottle observation has not been independently tested or verified, and no particular manufacturer or product is accused of counterfeiting.

Type at least two letters to search titles, summaries and topics.